Philip Morris International Inc. (NYSE: PM)

Philip Morris International Inc. is a leading international consumer goods company focused on delivering a smoke‑free future. The company evolves its portfolio beyond traditional tobacco to include smoke‑free products such as heat‑not‑burn devices, nicotine pouches, e‑vapor items, and wellness offerings. It continues to sell cigarettes while investing heavily in research and commercialization of reduced‑risk alternatives for adult smokers who would otherwise continue to smoke.

Philip Morris International Inc. generates revenue primarily from the sale of cigarettes and smoke‑free products, including heated tobacco units, nicotine pouches, e‑vapor cartridges, and related accessories. Revenue also comes from its wellness unit, Aspeya, which develops oral consumer products such as cannabinoid‑based offerings. Net revenues represent operating revenues from product sales, including shipping and handling charges billed to customers, net of sales promotions, incentives, and excise taxes.

The company operates through the following segments:

• International Smoke‑Free: This segment encompasses heat‑not‑burn products like IQOS, nicotine pouch brands such as ZYN, e‑vapor products like VEEV, wellness items, and consumer accessories such as lighters and matches, serving markets outside the United States.

• International Combustibles: This segment comprises the company’s cigarette portfolio and other combustible tobacco products sold in approximately 170 international markets, offering premium, mid‑price, and low‑price brands.

• U. S. (including wellness): This segment covers the United States smoke‑free business, including IQOS and ZYN products, as well as the wellness unit Aspeya, which focuses on oral consumer wellness offerings.

Philip Morris International Inc. holds a leading position in the global tobacco and nicotine industry, competing with firms such as British American Tobacco, Japan Tobacco, Imperial Brands, and Altria. Its competitive advantage stems from early investment in smoke‑free technology, robust scientific substantiation, and regulatory authorizations such as the FDA’s Modified Risk Tobacco Product orders for IQOS and ZYN, which support its strategy to reduce harm relative to continued smoking.

The company serves adult smokers and adult nicotine consumers worldwide, selling its products through retail channels, convenience stores, tobacco shops, and online platforms. Its customer base includes distributors, retailers, and ultimately adult consumers seeking cigarettes or smoke‑free alternatives.